Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Ipilimumab and Nivolumab with or without Hypofractionated Radiation Therapy in Treating Patients with Metastatic Melanoma

Trial Status: active

This phase II trial studies the side effects and how well ipilimumab and nivolumab work with or without hypofractionated radiation therapy in treating patients with melanoma that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving ipilimumab and nivolumab together with hypofractionated radiation therapy may work better in treating patients with metastatic melanoma.